CD86 and lung carcinoma: It was also found that platinum-containing drug oxaliplatin induced immunogenic cell death (ICD) in LLC cells, activating dendritic cells with CD80+CD86+ phenotype and enhancing cytotoxic CD8+ T cells in LLC tumor tissues, which resulted in tumor regression in a mouse model of lung cancer (191).